<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="67203">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01994239</url>
  </required_header>
  <id_info>
    <org_study_id>UC-0160/1204</org_study_id>
    <nct_id>NCT01994239</nct_id>
  </id_info>
  <brief_title>Comparison of HT Concomitant With RT vs RT Alone in Patients With a Detectable PSA After Prostatectomy</brief_title>
  <acronym>GETUG-AFU22</acronym>
  <official_title>A Multicenter Randomised Phase II Study Comparing the Efficiency of a HT Concomitant With RT vs RT Alone in the Salvage of Patients With a Detectable PSA After Prostatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to select the best therapeutic strategy in studying the
      effectiveness of the association of a short duration hormonal therapy and radiotherapy
      compared with radiotherapy alone, in patients with a detectable PSA after radical
      prostatectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study the effectiveness of the association of a short duration hormonal therapy by degarelix
      (Firmagon ®) and radiotherapy, with radiotherapy alone on survival without events in the
      treatment of detectable PSA after radical prostatectomy.

      122 patients should be included over a period of 2 years. Patients will be treated according
      to the following scheme:

        -  Arm A (61 patients) : Pelvic Radiotherapy: 46 Gy and prostate only boost up to 66 Gy

        -  Arm B (61 patients) : Arm A + hormonal therapy by degarelix during 6 months
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">June 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The efficacy of the combination of hormonal therapy by degarelix and radiotherapy on event-free survival</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival without biological event</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Biochemical recurrence was defined as a PSA &gt; nadir + 0.4 ng / mL confirmed by a second PSA&gt; nadir + 0.4 ng / mL in elevation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival without clinical event</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>The clinical recurrence will be defined by the discovery of a local recurrence in rectal examination, the appearance of metastases by imaging or biopsy, or clinical manifestation associated with malignant disease without elevated PSA but with histological documentation or imaging.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival without metastases</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute and late toxicities of the association of hormone therapy with radiotherapy</measure>
    <time_frame>up to 5 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>according CTC-AE v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicities of radiotherapy</measure>
    <time_frame>up to 5 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>according CTC-AE v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>up to 5 years after the end of the radiotherapy</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>QLQ-C30, QLQ-PR25 and IPSS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>kinetics of testosterone</measure>
    <time_frame>up to 12 months after the end of the radiotherapy and after biological release</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Adenocarcinoma of Prostate</condition>
  <arm_group>
    <arm_group_label>Radiation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pelvic radiotherapy
46 Gy in 23 fractions of 2 Gy.
prostate only-boost up to 66 Gy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiation and Degarelix</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiotherapy:
46 Gy in 23 fractions of 2 Gy.
prostate only-boost up to 66 Gy
Associated with hormonal therapy by degarelix:
beginning in parallel to radiotherapy for 6 months
First dose of 240 mg
Maintenance dose of 80 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Degarelix</intervention_name>
    <description>First dose of 240 mg 5 Maintenance doses of 80 mg every 28 days(+/-3d)</description>
    <arm_group_label>Radiation and Degarelix</arm_group_label>
    <other_name>Firmagon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Pelvic Radiotherapy</intervention_name>
    <description>46 Gy in 23 fractions Prostate only-boost up to 66 Gy</description>
    <arm_group_label>Radiation</arm_group_label>
    <arm_group_label>Radiation and Degarelix</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient with localized prostate adenocarcinoma treated with radical prostatectomy
             (whatever the initial prognostic stage)

          2. R0 or R1

          3. pN0 or pNx

          4. Post prostatectomy PSA ≥ 0,2 ng/mL measured between 1 month and 4 months after
             surgery and increasing to a second test performed between 1 et 8 month after the post
             prostatectomy dosage

          5. PSA ≤ 2 ng/mL at moment of the randomisation

          6. No clinical signs of progressive disease (bone scan or PET scan or  abdominal and
             pelvic scan or  MRI): N0, M0

          7. Neutrophils ≥ 1500/mm3; platelet count ≥ 100 000/mm3

          8. Bilirubin ≤ ULN; ALP, AST et ALT ≤ 1,5 ULN

          9. Creatinine &lt; 140 µmol/L (or  clearance &gt; 60mL/min)

         10. Normal fasting glucose

         11. ECOG ≤ 1

         12. Age &gt; 18 years

         13. Life expectancy ≥ 10 years

         14. Patients with invasive cancer in complete response for more than five years are
             eligible

         15. Patients who have received the information sheet and signed the informed consent form

         16. Patients with a public or a private health insurance coverage

        Exclusion Criteria:

          1. Prostate cancer histology other than adenocarcinoma

          2. Patients pN1, N1 and M1

          3. History of pelvic radiotherapy

          4. Contraindication to pelvic irradiation (eg, scleroderma, chronic inflammatory bowel
             disease, etc.).

          5. Testosterone ≤ 0,5 ng/mL

          6. History of surgical castration

          7. Previous treatment by hormonotherapy

          8. Antineoplastic treatment in progress

          9. History of another invasive cancer within 5 years before inclusion (with the
             exception of a basal cell skin carcinoma treated)

         10. Known pituitary adenoma

         11. Severe hypertension uncontrolled by appropriate treatment (160 mm Hg systolic and /
             or 90 mm ​​Hg diastolic)

         12. Patient with a corrected QT interval (using Fridericia correction) greater than 450
             msec

         13. Individual deprived of liberty or placed under the authority of a tutor

         14. Unable to undergo medical monitoring test for geographical, social or psychological
             reasons

         15. Known hypersensitivity to the treatment in test

         16. Administration of an investigational therapeutic within 28 days prior to the
             screening visit or more if treatment is likely to influence the outcome of this
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stéphane Guérif</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Poitiers</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laurent Salomon</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Henri Mondor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Muriel Habibian</last_name>
    <phone>+33 1 76 64 78 07</phone>
    <email>m-habibian@unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SALOMON Laurent</last_name>
      <phone>01 49 81 25 53</phone>
      <email>laurent.solomon@hmn.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Sainte-Marguerite</name>
      <address>
        <city>Hyeres</city>
        <zip>83400</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean F. Berdah, MD</last_name>
      <phone>33-4-9412-5555</phone>
      <email>jf.berdah@wanadoo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06088</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chu Caremeau</name>
      <address>
        <city>Nimes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Jean Godinot</name>
      <address>
        <city>Reims</city>
        <zip>51056</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.unicancer.fr</url>
    <description>Site UNICANCER</description>
  </link>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 20, 2013</lastchanged_date>
  <firstreceived_date>October 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate-Specific Antigen</keyword>
  <keyword>LHRH antagonist</keyword>
  <keyword>Radiotherapy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
